索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]孙宜 张瑞岩.防治冠状动脉病变进展的药物[J].国际心血管病杂志,2018,05:270-272,280.
点击复制

防治冠状动脉病变进展的药物(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2018年05期
页码:
270-272,280
栏目:
综述
出版日期:
2019-02-01

文章信息/Info

Title:
-
作者:
孙宜 张瑞岩
Author(s):
-
关键词:
冠状动脉粥样硬化;  斑块进展;  药物防治
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2018.05.004
文献标识码:
-
摘要:
冠状动脉病变进展将增加冠状动脉不良事件的风险,是心源性死亡的独立预测因素。他汀类药物、其他降脂药物、抗血小板药物、抑制肾素-血管紧张素-醛固酮系统的药物、抗炎药物、纳米转运药物和动脉粥样硬化疫苗等,均可抑制冠状动脉病变进展。该文主要介绍冠状动脉病变进展的药物防治现况
Abstract:
-

参考文献/References


[1] Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995[J]. Circulation, 1996, 94(8):2013-2020.
[2] Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease[J]. N Engl J Med, 2011, 365(22):2078-2087.
[3] Diamantis E, Kyriakos G, Quiles-Sanchez LV, et al. The anti-inflammatory effects of statins on coronary artery disease: an updated review of the literature[J]. Curr Cardiol Rev, 2017, 13(3):209-216.
[4] Ridker PM. The Jupiter trial: results, controversies, and implications for prevention[J]. Circ Cardiovasc Qual Outcomes, 2009, 2(3):279-285.
[5] Puri R, Nissen SE, Libby P, et al. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy[J]. Circulation, 2013, 128(22):2395-2403.
[6] Nakagomi A, Shibui T, Kohashi K, et al. Differential effects of atorvastatin and pitavastatin on inflammation, insulin resistance, and the carotid Intima-Media thickness in patients with dyslipidemia[J]. J Atheroscler Thromb, 2015, 22(11):1158-1171.
[7] Khurana S, Gupta S, Bhalla H, et al. Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome[J]. J Pharmacol Pharmacother, 2015, 6(3):130-135.
[8] Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice[J]. J Clin Invest, 2006, 116(11):2995-3005.
[9] Everett BM, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 inhibitors—the clinical benefit of lipid drugs[J]. N Engl J Med, 2015, 373(17):1588-1591.
[10] Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial[J]. JAMA, 2016, 316(22):2373-2384.
[11] Su G, Sun G, Liu H, et al. Niacin suppresses progression of atherosclerosis by inhibiting vascular inflammation and apoptosis of vascular smooth muscle cells[J]. Med Sci Monit, 2015, 21:4081-4089.
[12] Capra V, Bäck M, Angiolillo DJ, et al. Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation[J]. J Thromb Haemost, 2014, 12(2):126-137.
[13] Gremmel T, Koppensteiner R, Kaider A, et al. Impact of variables of the P-selectin—P-selectin glycoprotein ligand-1 axis on leukocyte-platelet interactions in cardiovascular disease[J]. Thromb Haemost, 2015, 113(4):806-812.
[14] Mezouar S, Darbousset R, Dignat-George F, et al. Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo[J]. Int J Cancer, 2015, 136(2):462-475.
[15] Takeda M, Yamashita T, Shinohara M, et al. Beneficial effect of anti-platelet therapies on atherosclerotic lesion formation assessed by phase-contrast X-ray CT imaging[J]. Int J Cardiovasc Imaging, 2012, 28(5):1181-1191.
[16] Dobesh PP, Patel M. The Parthenon clinical development program: the role of ticagrelor in patients with atherothrombotic disease[J]. Cardiovasc Drugs Ther, 2017, 31(4):433-444.
[17] Preusch MR, Rusnak J, Staudacher K, et al. Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis[J]. Drug Des Devel Ther, 2016, 10:2691-2699.
[18] Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients[J]. N Engl J Med, 2000, 342(3):145-153.
[19] Mason RP. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil[J]. Vasc Health Risk Manag, 2011, 7:405-416.
[20] Zinellu A, Sotgia S, Mangoni AA, et al. Effects of ramipril and telmisartan on plasma concentrations of low molecular weight and protein thiols and carotid intima media thickness in patients with chronic kidney disease[J]. Dis Markers, 2016, 2016:1821596.
[21] Bäck M, Hansson GK. Leukotriene receptors in atherosclerosis[J]. Ann Med, 2006, 38(7):493-502.
[22] Ingelsson E, Yin L, Bäck M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease[J]. J Allergy Clin Immunol, 2012, 129(3):702-707.
[23] Fisk M, Gajendragadkar PR, Mäki-Petäjä KM, et al. Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease[J]. Am J Cardiovasc Drugs, 2014, 14(3):155-165.
[24] Sarov-Blat L, Morgan JM, Fernandez P, et al. Inhibition of p38 mitogen-activated protein kinase reduces inflammation after coronary vascular injury in humans[J]. Arterioscler Thromb Vasc Biol, 2010, 30(11):2256-2263.
[25] Sharma PA, Maheshwari R, Tekade M, et al. Nanomaterial based approaches for the diagnosis and therapy of cardiovascular diseases[J]. Curr Pharm Des, 2015, 21(30):4465-4478.
[26] Tang J, Lobatto ME, Hassing L, et al. Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation[J]. Sci Adv, 2015, 1(3):e1400223.
[27] Zhang J, Nie S, Martinez-Zaguilan R, et al. Formulation, characteristics and antiatherogenic bioactivities of CD36-targeted epigallocatechin gallate(EGCG)-loaded nanoparticles[J]. J Nutr Biochem, 2016, 30:14-23.
[28] Fredman G, Kamaly N, Spolitu S, et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice [J]. Sci Transl Med, 2015, 7(275):275ra20.
[29] Kimura T, Tse K, Sette A, et al. Vaccination to modulate atherosclerosis[J]. Autoimmunity, 2015, 48(3):152-160.
[30] Chyu KY, Dimayuga PC, Shah PK. Vaccine against arteriosclerosis: an update[J]. Ther Adv Vaccines, 2017, 5(2):39-47.

备注/Memo

备注/Memo:
作者单位:200025 上海交通大学医学院附属瑞金医院心脏科
更新日期/Last Update: 2018-09-30